5,7-disubstituted thiazolo[4,5-d]pyrimidines for the selective inhibition of chemokine receptors

US7960395B2 · kind B2 · utility

Assignee

• ASTRAZENECA AB · SE

Inventors

• Rolf Johansson · Huddinge, SE
• Sofia Karlstrom · Macclesfield, GB
• Annika Kers · Malung, SE
• Gunnar Nordvall · Gately Drive, SE
• Tobias Rein · Gately Drive, SE
• Can Slivo · Malung, SE

Key dates

• Filing date: Sep 27, 2007
• Grant date: Jun 14, 2011
• Expiry date: Apr 17, 2029

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I)wherein R1, R2, R3, R4 and n are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.